Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- The Catholic University of Korea Seoul St. Mary’s Hospital
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intravenous, Oral
01
Overview
This combination chemotherapy regimen, developed and investigated by Seoul St. Mary's Hospital, consists of intraperitoneal (IP) paclitaxel administered alongside systemic XELOX (capecitabine and oxaliplatin). It is specifically designed as a first-line treatment for patients with advanced gastric cancer complicated by peritoneal metastasis. The rationale for IP administration is to exploit the peritoneal-plasma barrier, allowing for significantly higher concentrations of paclitaxel within the peritoneal cavity to directly target metastatic nodules while minimizing systemic side effects. Paclitaxel functions as a microtubule stabilizer, oxaliplatin as a platinum-based DNA cross-linking agent, and capecitabine as a prodrug of 5-fluorouracil that inhibits thymidylate synthase.
- Other names
- IP paclitaxel + XELOXIntraperitoneal paclitaxel plus XELOXIP-P + XELOX
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on paclitaxel + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + capecitabine + oxaliplatin.